GLP-1 myths on TikTok: what @doctoraunique is likely getting right and wrong

What did @doctoraunique actually say?

This is genuinely difficult to assess. The transcript as captured appears to be heavily distorted, likely a mix of Spanish and garbled audio transcription. Phrases like "seropunto vinti sin comi legremos" do not correspond to recognizable medical Spanish or English terminology. The word "Ocempique" appears to be a phonetic rendering of Ozempic, and "Lados" may refer to sides or side effects in Spanish. Without a clean audio source, we are working with fragments.

What we can piece together is that the creator seems to be discussing Ozempic (semaglutide) in a Spanish-language format, possibly responding to a follower question about dosing or side effects. The phrase structure suggests a before-and-after comparison, potentially about eating habits or tolerability. We cannot responsibly put specific words in their mouth based on this transcript.

Does the science back this up?

If the video is about semaglutide and eating behavior, the underlying science is actually well-established, even if the delivery here is unclear. Semaglutide works primarily by activating GLP-1 receptors in the brain and gut, slowing gastric emptying and reducing appetite signals. That much is not controversial.

Multiple large trials confirm these mechanisms. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that weekly semaglutide 2.4 mg produced around 15 percent mean weight loss over 68 weeks compared to placebo. The appetite suppression effect is real, dose-dependent, and tied to slower gastric emptying. Nausea, which is a common complaint and likely what "sin comi" (without eating) references, peaks during dose escalation and affects roughly 44 percent of patients in STEP trials. This is not a side effect to minimize.

What did they get wrong (or right)?

Without a legible transcript, we cannot verify specific claims, so this is where we have to be honest about limits. What we can say is that Spanish-language GLP-1 content on TikTok is often oversimplified, and 36,000 views on an unclear medical claim is a real public health concern regardless of the creator's credentials.

The structure of the transcript suggests a comparison between two states, possibly before and after starting semaglutide. If the creator is implying that reduced appetite is purely positive and expected at every dose, that is partially misleading. Side effects like nausea, vomiting, and gastroparesis risk are not minor footnotes. Davies et al. (2021, Lancet Diabetes and Endocrinology) found that gastrointestinal side effects caused discontinuation in a meaningful subset of patients. Framing appetite loss as a simple benefit without discussing GI tolerability does patients a disservice.

What should you actually know?

If you are starting semaglutide or tirzepatide, here is what actually matters. Dose escalation schedules exist for a reason. Starting at 0.25 mg weekly for semaglutide and stepping up gradually is not optional cautious advice, it is the protocol that makes the drug tolerable for most people. Skipping meals because you feel too nauseated is different from the intended appetite reduction, and persistent vomiting warrants a call to your prescriber, not a TikTok comment section.

Spanish-speaking patients are significantly underserved by high-quality GLP-1 education. A 2023 analysis in JAMA Health Forum noted that Hispanic adults with obesity and type 2 diabetes are less likely to receive GLP-1 prescriptions despite higher disease burden. That gap is real, and creators filling it with accessible content are doing something valuable. But accessible does not mean accurate by default, and unclear claims in any language can lead to real harm.